Ubiquitin at the crossroad of cell death and survival

Chinese Journal of Cancer

Volumn 32, Issue 12, 2013, Pages 640-647

  Chen, Yu Shan ^a   Qiu, Xiao Bo ^a  

^a Beijing Normal University   (China)

Author keywords

Apoptosis; Autophagy; BRUCE; Caspase; NF B; p53; Ubiquitin; Ubiquitination

Indexed keywords

APOPTOSIS INDUCING FACTOR; BECLIN 1; BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PEVONEDISTAT; POLYUBIQUITIN; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P53; TUMOR NECROSIS FACTOR RECEPTOR; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; AUTOPHAGY; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROTECTION; CELL STRESS; CELL SURVIVAL; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; PROTEIN DEGRADATION; REVIEW; TUMOR GROWTH; UBIQUITINATION;

APOPTOSIS; AUTOPHAGY; CELL DEATH; CELL SURVIVAL; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEOLYSIS; UBIQUITIN; UBIQUITINATION;

EID: 84885472912     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10283     Document Type: Review

References (88)

1. Giampietri C, Petrungaro S, Padula F, et al. Autophagy modulators sensitize prostate epithelial cancer cell lines to TNF-alphadependent apoptosis. Apoptosis, 2012:1-13.
2. Ciechanover A, Ben-Saadon R. N-terminal ubiquitination: more protein substrates join in. Trends Cell Biol, 2004,14:103-106.
3. Deng L, Wang C, Spencer E, et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell, 2000,103:351.
4. Iwai K, Tokunaga F. Linear polyubiquitination: a new regulator of NF-κB activation. EMBO reports, 2009,10:706-713.
5. Wenzel DM, Lissounov A, Brzovic PS, et al. UBCH7 reactivity profile reveals parkin and HHARI to be RING/HECT hybrids. Nature, 2011,474:105-108.
6. Wang X, Herr RA, Chua WJ, et al. Ubiquitination of serine, threonine, or lysine residues on the cytoplasmic tail can induce ERAD of MHC-I by viral E3 ligase mK3. J Cell Biol, 2007,177:613-624.
7. Tokarev AA, Munguia J, Guatelli JC. Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu. J Virol, 2011,85:51-63.
8. Wäsch R, Engelbert D. Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene, 2005,24:1-10.
9. Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer, 2006,6:776-788.
10. Evans PC, Ovaa H, Hamon M, et al. Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J, 2004,378:727.
11. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer cell, 2004,5:417-421.
12. Ostrowska H. The ubiquitin-proteasome system: a novel target for anticancer and anti-inflammatory drug research. Cell Mol Biol Lett, 2008,13:353-365.
13. Jia L, Gopinathan G, Sukumar JT, et al. Blocking autophagy prevents bortezomib-induced NF-kappaB activation by reducing I-kappaBalpha degradation in lymphoma cells. PloS one, 2012,7:e32584.
14. Suraweera A, Munch C, Hanssum A, et al. Failure of amino acid homeostasis causes cell death following proteasome inhibition. Mol Cell, 2012,48:242-253.
15. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade™(Bortezomib). Cancer Invest, 2004,22:304-311.
16. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med, 2003,348:2609-2617.
17. Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitinproteasome system. Nat Rev Drug Discov, 2006,5:596-613.
18. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Revi Mol Cell Biol, 2005,6:9-20.
19. Sakata E, Yamaguchi Y, Miyauchi Y, et al. Direct interactions between NEDD8 and ubiquitin E2 conjugating enzymes upregulate cullin-based E3 ligase activity. Nat Struct Mol Biol, 2007,14:167-168.
20. Soucy TA, Smith PG, Milhollen MA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature, 2009,458:732-736.
21. Swords RT, Kelly KR, Smith PG, et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood, 2010,115:3796-3800.
22. Ashkenazi A. Targeting death and decoy receptors of the tumournecrosis factor superfamily. Nat Rev Cancer, 2002,2:420-430.
23. Yuan J, Yankner BA. Apoptosis in the nervous system. Nature, 2000,407:802-809.
24. Zou H, Henzel WJ, Liu X, et al. Apaf-1, a human protein homologous to C. Elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell, 1997,90:405-414.
25. Dimmeler S, Breitschopf K, Haendeler J, et al. Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway. J Exp Med, 1999,189:1815-1822.
26. Shimizu S, Takehara T, Hikita H, et al. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenibinduced apoptosis in human hepatocellular carcinoma. J Hepatol, 2010,52:698-704.
27. Nakano H, Miyazawa T, Kinoshita K, et al. Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int J Cancer, 2010,127:1072-1080.
28. Li B, Dou QP. Bax degradation by the ubiquitin/proteasomedependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A, 2000,97:3850-3855.
29. Oh JM, Kim SH, Cho EA, et al. Human papillomavirus type 16 E5 protein inhibits hydrogen peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells. Carcinogenesis, 2010,31:402-410.
30. Magiera M, Mora S, Mojsa B, et al. Trim17-mediated ubiquitination and degradation of Mcl-1 initiate apoptosis in neurons. Cell Death Differ, 2013,20:281-292.
31. Huang NJ, Zhang L, Tang W, et al. The Trim39 ubiquitin ligase inhibits APC/CCdh1-mediated degradation of the Bax activator MOAP-1. J Cell Biol, 2012,197:361-367.
32. Beverly LJ, Lockwood WW, Shah PP, et al. Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1. Proc Natl Acad Sci U S A, 2012,109:E119-E126.
33. Wilson R, Goyal L, Ditzel M, et al. The DIAP1 RING finger mediates ubiquitination of Dronc and is indispensable for regulating apoptosis. Nat Cell Biol, 2002,4:445-450.
34. Hawkins CJ, Wang SL, Hay BA. A cloning method to identify caspases and their regulators in yeast: identification of Drosophila IAP1 as an inhibitor of the Drosophila caspase DCP-1. Proc Natl Acad Sci U S A, 1999,96:2885.
35. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res, 2000,6:1796-1803.
36. Suzuki Y, Nakabayashi Y, Takahashi R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its antiapoptotic effect in Fas-induced cell death. Proc Natl Acad Sci U S A, 2001,98:8662.
37. Schile AJ, García-Fernández M, Steller H. Regulation of apoptosis by XIAP ubiquitin-ligase activity. Genes Dev, 2008,22:2256-2266.
38. Qi Y, Xia P. Cellular inhibitor of apoptosis protein-1 (cIAP1) plays a critical role in β-cell survival under endoplasmic reticulum stress: promoting ubiquitination and degradation of C/EBP homologous protein (CHOP). J Biol Chem, 2012,287:32236-32245.
39. Lewis EM, Wilkinson AS, Davis NY, et al. Nondegradative ubiquitination of apoptosis inducing factor (AIF) by X-linked inhibitor of apoptosis at a residue critical for AIF-mediated chromatin degradation. Biochemistry, 2011,50:11084-11096.
40. Mei Y, Hahn AA, Hu S, et al. The USP19 deubiquitinase regulates the stability of c-IAP1 and c-IAP2. J Biol Chem, 2011,286:35380-35387.
41. Du C, Fang M, Li Y, et al. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell, 2000,102:33-42.
42. Olson MR, Holley CL, Yoo SJ, et al. Reaper is regulated by IAPmediated ubiquitination. J Biol Chem, 2003,278:4028-4034.
43. Qiu XB, Markant SL, Yuan J, et al. Nrdp1-mediated degradation of the gigantic IAP, BRUCE, is a novel pathway for triggering apoptosis. EMBO J, 2004,23:800-810.
44. Hao Y, Sekine K, Kawabata A, et al. Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nat Cell Biol, 2004,6:849-860.
45. Qiu XB, Goldberg AL. The membrane-associated inhibitor of apoptosis protein, BRUCE/Apollon, antagonizes both the precursor and mature forms of Smac and caspase-9. J Biol Chem, 2005,280:174-182.
46. Bhatt P, d'Avout C, Kane NS, et al. Specific domains of nucleolin interact with Hdm2 and antagonize Hdm2-mediated p53 ubiquitination. FEBS J, 2012,279:370-383.
47. Sun XX, Challagundla KB, Dai MS. Positive regulation of p53 stability and activity by the deubiquitinating enzyme Otubain 1. EMBO J, 2011,31:576-592.
48. Lee HR, Choi WC, Lee S, et al. Bilateral inhibition of HAUSP deubiquitinase by a viral interferon regulatory factor protein. Nat Struct Mol Biol, 2011,18:1336-1344.
49. Amson R, Pece S, Lespagnol A, et al. Reciprocal repression between P53 and TCTP. Nat Med, 2011,18:91-99.
50. Li Y, Zhao L, Sun H, et al. Gene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells. PloS one, 2012,7:e44254.
51. Ikeda F, Deribe YL, Skånland SS, et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis. Nature, 2011,471:637-641.
52. Wertz IE, Dixit VM. Signaling to NF-κB: regulation by ubiquitination. Cold Spring Harb Perspect Biol, 2010,2:a003350.
53. Chen F, Demers LM, Shi X. Upstream signal transduction of NFkappaB activation. Curr Drug Targets Inflamm Allergy, 2002,1:137-149.
54. Chen L, Siddiqui S, Bose S, et al. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgendependent but not castrate-resistant prostate cancer cells. Cancer Res, 2010,70:5994-6003.
55. Limpert AS, Carter BD. Axonal neuregulin 1 type III activates NF-κB in schwann cells during myelin formation. J Biol Chem, 2010,285:16614-16622.
56. Lockshin RA, Zakeri Z. Apoptosis, autophagy, and more. Int J Biochem Cell Biol, 2004,36:2405-2419.
57. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer, 2012,12:401-410.
58. Mizushima N. Autophagy: process and function. Genes Dev, 2007,21:2861-2873.
59. Kirkin V, McEwan DG, Novak I, et al. A role for Ubiquitin in selective autophagy. Mol Cell, 2009,34:259-269.
60. Thurston TLM, Ryzhakov G, Bloor S, et al. The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitincoated bacteria. Nat Immunol, 2009,10:1215-1221.
61. Wei Y, Pattingre S, Sinha S, et al. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell, 2008,30:678-688.
62. Shi CS, Kehrl JH. TRAF6 and A20 regulate lysine 63-linked ubiquitination of Beclin-1 to control TLR4-induced autophagy. SciSignal, 2010,3:ra42.
63. Wei Y, Sinha S, Levine B. Dual role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation. Autophagy, 2008,4:949-951.
64. Djavaheri-Mergny M, Maiuri M, Kroemer G. Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene, 2010,29:1717-1719.
65. Liu J, Xia H, Kim M, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell, 2011,147:223-234.
66. Crighton D, Wilkinson S, O'Prey J, et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell, 2006, 126:121-134.
67. Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet, 2004,36:585-595.
68. Maiuri MC, Malik SA, Morselli E, et al. Stimulation of autophagy by the p53 target gene Sestrin2. Cell Cycle, 2009,8:1571-1576.
69. Scherz-Shouval R, Weidberg H, Gonen C, et al. p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under prolonged starvation. Proc Natl Acad Sci U S A, 2010,107:18511-18516.
70. Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets, 2005,5:3-8.
71. Menin C, Scaini MC, De Salvo GL, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst, 2006,98:285-288.
72. Lind H, Zienolddiny S, Ekstrøm PO, et al. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer, 2006,119:718-721.
73. Masuya D, Huang C, Liu D, et al. The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways. J Pathol, 2006,208:724-732.
74. Meetei AR, de Winter JP, Medhurst AL, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet, 2003,35:165-170.
75. Hu S, Du M, Park S, et al. cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J Clin Invest, 2006,116:174-181.
76. Casas S, Nagy B, Elonen E, et al. Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia. Leuk Lymphoma, 2003,44:1935-1941.
77. Hoffman MA, Ohh M, Yang H, et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet, 2001,10:1019-1027.
78. Kondo K, Klco J, Nakamura E, et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell, 2002,1:237-246.
79. Hengstermann A, D'silva MA, Kuballa P, et al. Growth suppression induced by downregulation of E6-AP expression in human papillomavirus-positive cancer cell lines depends on p53. J Virol, 2005,79:9296-9300.
80. Winston JT, Strack P, Beer-Romero P, et al. The SCFβ-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro. Genes Dev, 1999,13:270-283.
81. Yuan WC, Lee YR, Huang SF, et al. A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer Cell, 2011,20:214-228.
82. Schwickart M, Huang XD, Lill JR, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature, 2009,463:103-107.
83. Zhao D, Zheng HQ, Zhou Z, et al. The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res, 2010,70:4728-4738.
84. Ho KC, Zhou Z, She YM, et al. Itch E3 ubiquitin ligase regulates large tumor suppressor 1 tumor-suppressor stability. Proc Natl Acad Sci U S A, 2011,108:4870-4875.
85. Salah Z, Melino G, Aqeilan RI. Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity. Cancer Res, 2011,71:2010-2020.
86. Sarkar TR, Sharan S, Wang J, et al. Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBPδ expression and contributes to transformation of breast tumor cells. Mol Cell Biol, 2012,32:320-332.
87. Razinia Z, Baldassarre M, Bouaouina M, et al. The E3 ubiquitin ligase specificity subunit ASB2α targets filamins for proteasomal degradation by interacting with the filamin actin-binding domain. J Cell Sci, 2011,124:2631-2641.
88. Duan S, Cermak L, Pagan JK, et al. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature, 2011,481:90-93.